<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766362</url>
  </required_header>
  <id_info>
    <org_study_id>Creuzot Innov 2010</org_study_id>
    <nct_id>NCT01766362</nct_id>
  </id_info>
  <brief_title>Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.</brief_title>
  <acronym>Pascal</acronym>
  <official_title>Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to show that PRPC performed in a single session using a Pascal laser
      leads to better management of the disease (better rate of regression of neovessels, lower
      risk of a loss of visual acuity in the long term related to macular edema), a saving of time
      and better comfort for both patient and doctor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular thickness</measure>
    <time_frame>9 months after the start of traitement</time_frame>
    <description>Central macular thickness at 9 months after the start of PRPC using Pascal laser.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Type 1 or 2 With Diabetic Retinopathy.</condition>
  <arm_group>
    <arm_group_label>A session</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Four sessions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Every session are spaced out of month</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PRPC using Pascal laser</intervention_name>
    <arm_group_label>A session</arm_group_label>
    <arm_group_label>Four sessions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 1 or 2

          -  Subjects with severe non-proliferative or early proliferative diabetic retinopathy
             (according to the Alfediam classification)

          -  Subjects with central macular thickness less than or equal to 350 µm according to
             spetralis OCT

          -  Subjects registered with a social security agency

          -  Subjects who have provided written informed consent

          -  Subjects aged 18 or above

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding women

          -  Patients presenting a contra-indication to Mydriaticum and Neosynephrine

          -  History of glaucoma or non-controlled ocular hypertension

          -  Blindness in one eye

          -  History of renal insufficiency requiring dialysis, or kidney or pancreas
             transplantation

          -  Unbalanced diabetes requiring, in the previous 4 months, intensive insulin therapy.

          -  Central macular thickness greater than 350 µm

          -  Visual acuity less than 20/32 measured using an ETDRS chart

          -  Proliferative diabetic retinopathy associated with &quot;high risk factors&quot; (extensive
             prepapillary neovessels and/or preretinal or prepapillary neovessels associated with
             preretinal of intravitreal hemorrhage)

          -  Macular edema due to causes other than diabetic retinopathy (venous occlusion,
             uveitis) or occurring in a context of vitreomacular traction

          -  Already started PRPC

          -  History of eye surgery or YAG laser capsulotomy performed during the preceding 6
             months

          -  Subjects under legal supervision or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine CREUZOT-GARCHER</last_name>
    <phone>3 80 29 51 73</phone>
    <phone_ext>+33</phone_ext>
    <email>catherine.creuzot-garcher@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CREUZOT-GARCHER</last_name>
      <phone>3 80 29 51 73</phone>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine CREUZOT-GARCHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent KODJIKIAN</last_name>
      <phone>4 26 10 93 21</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Laurent KODJIKIAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zohra Nacera BOUSSAID</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale MASSIN</last_name>
      <phone>1 49 95 85 44</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Pascale MASSIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali ERGINAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeynep VICTOR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien BRUNEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bénédicte DUPAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PEROL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

